874902-19-9

Basic information

• Product Name: 5-[[(1,1'-BIPHENYL)-4-YL]METHYL]-N,N-DIMETHYL-1H-TETRAZOLE-1-CARBOXAMIDE
• Synonyms: LY 2183240;5-[[(1,1'-BIPHENYL)-4-YL]METHYL]-N,N-DIMETHYL-1H-TETRAZOLE-1-CARBOXAMIDE;5-(biphenyl-4-ylMethyl)-N,N-diMethyl-1H-tetrazole-1-carboxaMide;LY-2183240 MN-25;1H-Tetrazole-1-carboxamide, 5-([1,1′-biphenyl]-4-ylmethyl)-N,N-dimethyl-;5-Biphenyl-4-ylmethyl-tetrazole-1-carboxylic acid dimethylamide;N,N-dimethyl-5-[(4-phenylphenyl)methyl]tetrazole-1-carboxamide;LY2183240/LY-2183240
• CAS NO: 874902-19-9
• Molecular Formula: C17H17N5O
• Molecular Weight: 307.34978
• Mol File: 874902-19-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 87-88℃
• Boiling Point: 506.103 °C at 760 mmHg
• Flash Point: 259.882 °C
• Appearance: /
• Density: 1.21
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.64
• Storage Temp.: Store at +4°C
• Solubility: Soluble in DMSO (greater than 25 mg/ml) or in Ethanol (up to 15 mg/ml).
• PKA: 0.01±0.10(Predicted)
• Stability: Stable for 1 year as supplied. Solutions in DMSO of ethanol may be stored at -20°C for up to 1 month
• CAS DataBase Reference: 5-[[(1,1'-BIPHENYL)-4-YL]METHYL]-N,N-DIMETHYL-1H-TETRAZOLE-1-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[[(1,1'-BIPHENYL)-4-YL]METHYL]-N,N-DIMETHYL-1H-TETRAZOLE-1-CARBOXAMIDE(874902-19-9)
• EPA Substance Registry System: 5-[[(1,1'-BIPHENYL)-4-YL]METHYL]-N,N-DIMETHYL-1H-TETRAZOLE-1-CARBOXAMIDE(874902-19-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 874902-19-9(Hazardous Substances Data)

Usage

Description

5-[[(1,1'-BIPHENYL)-4-YL]METHYL]-N,N-DIMETHYL-1H-TETRAZOLE-1-CARBOXAMIDE, also known as LY2183240, is a synthetic compound that acts as a potent inhibitor of fatty acid amide hydrolase (FAAH) activity, cellular anandamide uptake, and enzymatic hydrolysis of anandamide. It is a synthetic cannabinoid with potential therapeutic applications.

Uses

Used in Pharmaceutical Industry:
5-[[(1,1'-BIPHENYL)-4-YL]METHYL]-N,N-DIMETHYL-1H-TETRAZOLE-1-CARBOXAMIDE is used as a research chemical for the development of new drugs targeting the endocannabinoid system. Its ability to inhibit FAAH activity and anandamide uptake makes it a potential candidate for the treatment of various disorders related to the endocannabinoid system, such as pain, inflammation, and neurodegenerative diseases.
Used in Neuroscience Research:
5-[[(1,1'-BIPHENYL)-4-YL]METHYL]-N,N-DIMETHYL-1H-TETRAZOLE-1-CARBOXAMIDE is used as a research tool in neuroscience to study the role of the endocannabinoid system in various physiological and pathological processes. Its potent inhibitory effects on FAAH and anandamide uptake allow researchers to investigate the mechanisms underlying the endocannabinoid system's involvement in cognitive function, mood regulation, and other neurological conditions.
Used in Drug Development:
5-[[(1,1'-BIPHENYL)-4-YL]METHYL]-N,N-DIMETHYL-1H-TETRAZOLE-1-CARBOXAMIDE is used as a lead compound in the development of new synthetic cannabinoids with potential therapeutic applications. Its unique chemical structure and pharmacological properties make it a valuable starting point for the design and synthesis of novel compounds with improved efficacy, selectivity, and safety profiles.
Used in Drug Screening and Assay Development:
5-[[(1,1'-BIPHENYL)-4-YL]METHYL]-N,N-DIMETHYL-1H-TETRAZOLE-1-CARBOXAMIDE is used as a reference compound in drug screening and assay development for the identification and evaluation of new FAAH inhibitors and other modulators of the endocannabinoid system. Its well-defined pharmacological profile and potency enable researchers to develop reliable and sensitive assays for the discovery of new therapeutic agents targeting the endocannabinoid system.

Biological Activity

Novel and highly potent blocker of anandamide uptake (IC 50 = 270 pM). Inhibits fatty acid amide hydrolase (FAAH) activity (IC 50 = 12.4 nM). Following i.p. administration in rats, increases brain anandamide concentration and exerts antinociceptive effects in formalin model of pain.

References

1) Moore et al., (2005), Identification of a high-affinity binding site involved in the transport of endocannabinoids; Proc. Natl. Acad. Sci. USA, 102 17852 2) Ortar et al. (2008), Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: A critical revision; Eur. .J. Med. Chem., 43 62 3) Alexander and Cravatt (2006), The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases; J. Am. Chem. Soc., 128 9699 4) Dickason-Chesterfield et al. (2006), Pharmacological Characterization of Endocannabinoid Transport and Fatty Acid Amide Hydrolase Inhibitors; Cell. Mol. Neurobiol., 26 405

InChI:InChI=1/C17H17N5O/c1-21(2)17(23)22-16(18-19-20-22)12-13-8-10-15(11-9-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3

Upstream product

• 79-44-7 N,N-Dimethylcarbamoyl chloride 
• 31603-77-7 4-biphenylacetonitrile 

Relevant articles and documents

The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases

How lipid transmitters move within and between cells to communicate signals remains an important and largely unanswered question. Integral membrane transporters, soluble lipid-binding proteins, and metabolic enzymes have all been proposed to collaborative

INHIBITORS OF FATTY ACID AMIDE HYDROLASE AND MONOACYLGLYCEROL LIPASE FOR MODULATION OF CANNABINOID RECEPTORS

Disclosed are compounds and compositions that inhibit the action of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL), methods of inhibiting FAAH and MGL, methods of modulating cannabinoid receptors, and methods of treating various disorders related to modulation of cannabinoid receptors.